MiniMed Group, Inc. (MMED), the diabetes medical technology company spun off from Medtronic (MDT) in its March 2026 initial public offering (IPO), has rallied nearly 85% from its 52-week low of $10.65 to trade near $19.60. Now investors are asking whether the stock can climb another 27% to hit $25 — the highest analyst price target on Wall Street and a level that would represent fresh all-time highs for the newly public company.
The $25 price target has emerged as a widely discussed milestone because it represents the high-water mark among Wall Street analyst estimates. BTIG reiterated its $25 target in July 2026, basing its valuation on roughly 9x to 10x forward enterprise value-to-adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). UBS Group initiated coverage with a Buy rating and a $25 target in late July, while Wells Fargo raised its target to $26 in June. Goldman Sachs set a nearby $24 target earlier in the year. With the stock trading just below $20, the $25 level has become the focal point of the debate around MiniMed's growth trajectory.
MiniMed Group is a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of diabetes management solutions. Its platform includes Automated Insulin Delivery (AID) systems — insulin pumps, CGM sensors, and algorithms that work together to mimic a healthy pancreas — as well as Smart Multiple Daily Injection (MDI) systems featuring smart insulin pens. The company generates revenue across more than 80 countries and posted $3.10 billion in sales during fiscal 2026, representing 14.3% year-over-year growth. International markets accounted for roughly 70% of total revenue, growing at a 20.6% reported rate. The company holds more than 2,000 patents and operates as the only full-stack provider in the diabetes technology space — meaning it owns the pump, sensor, algorithm, and software ecosystem under one roof.
Several catalysts could power the stock toward the $25 mark. The MiniMed Flex system, a next-generation smartphone-controlled insulin pump that received FDA clearance ahead of schedule, launched commercially in the United States in June 2026. This product represents the company's smallest and most discreet pump yet and could help recapture U.S. market share after years of stagnation — U.S. sales grew just 1.5% in fiscal 2026.
International momentum remains strong, with organic revenue growth of 11.2% outside the United States. The recent launch of Instinct sensors in Europe, developed through a partnership with Abbott (ABT), expands sensor choice for patients. Meanwhile, the MiniMed Go smart MDI platform and the Fit patch pump — currently in development — represent additional growth vectors that could accelerate revenue over the next two years.
Wall Street expects MiniMed to approach profitability inflection. Analyst consensus projects adjusted EPS of approximately $0.65 for fiscal 2027, a dramatic swing from the -$1.30 loss per share reported in fiscal 2026. If the company delivers on margin expansion targets — moving adjusted EBITDA margins from the mid-teens toward 25% over several years — the valuation case for $25 strengthens considerably.
The underlying market tailwind is also significant. The global diabetes technology market is valued at over $18 billion and growing at a high-teens percentage rate, yet remains only about 7% penetrated. Rising diabetes prevalence worldwide provides a durable secular growth backdrop.
Despite the optimistic analyst consensus, meaningful risks stand between MiniMed and the $25 target. The company's latest quarterly report underscored these challenges: MiniMed posted a loss of $0.68 per share, missing consensus estimates by a wide margin, despite delivering $837 million in revenue that beat expectations. Net losses widened from $213 million in fiscal 2025 to $333 million in fiscal 2026.
Competition remains fierce. DexCom (DXCM) and Abbott dominate the CGM market, while Insulet (PODD) leads in the patch pump category. MiniMed's U.S. pump sales have been essentially flat, with approximately 145,000 new pumps sold worldwide in fiscal 2026 — unchanged from the prior year. Regaining momentum in its home market is essential for the stock to command a higher valuation multiple.
Additionally, Medtronic retains a roughly 90% ownership stake following the IPO, meaning the public float is relatively small and the stock may face ongoing overhang risk if Medtronic decides to distribute or sell additional shares.
The analyst community is broadly bullish but with a range that reflects genuine uncertainty. Of 12 to 13 analysts covering the stock, the overwhelming majority rate it a Buy or equivalent. The consensus 12-month price target sits near $21, representing about 7% upside from current levels. However, the range is wide: Piper Sandler maintains a Hold rating with a $16 target, while BTIG, UBS, and Wells Fargo see $25 to $26 as achievable. This dispersion highlights that the $25 level is an optimistic but credible scenario — not the base case for the broader analyst community.
From a technical standpoint, MiniMed shares have been in a strong recovery trend since bottoming at $10.65 in May 2026. The rally has pushed the stock toward its 52-week high of $20.48, an area that now represents the first critical resistance zone. A decisive breakout above $20.48 on strong volume would confirm that buyers are willing to absorb supply at all-time highs — a necessary precondition for a sustained move toward $25.
On the downside, the $15–$16 area has acted as reliable support, reinforced by the 50-day moving average and Piper Sandler's conservative price target. A breakdown below this zone would invalidate the near-term bullish thesis. The psychological round number of $20 also serves as an important battleground where buyers and sellers are currently contending for control.
Navigating opportunities in stocks like MiniMed Group requires timely, data-driven insight. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and AI-powered analysis. Rather than relying on delayed manual research, traders can use these signals to identify emerging opportunities, track existing positions, and stay ahead of shifts in market sentiment. When a stock is approaching a critical resistance level like $20.48 or testing support near $15, real-time AI-generated signals can help investors make more informed decisions without second-guessing every market fluctuation. Explore the platform to see how AI Daily Buy/Sell Signals can complement your trading process.
The question of whether MiniMed Group can reach $25 hinges on execution. The company operates in a large, underpenetrated market with genuine competitive advantages as the only full-stack diabetes technology provider. Multiple respected Wall Street firms have placed $25 targets on the stock, and the product pipeline — including MiniMed Flex, Go, Fit, and new sensor integrations — provides concrete catalysts that could drive revenue growth and margin expansion over the next 12 to 18 months.
However, the path to $25 is far from guaranteed. Persistent unprofitability, flat U.S. pump adoption, intense competitive pressure, and a recent history of earnings misses argue for caution. The stock must first clear the $20.48 all-time high before $25 becomes a realistic near-term objective. Investors should monitor upcoming earnings reports, U.S. commercial execution of MiniMed Flex, and any updates to Medtronic's ownership position as key signposts on the road to $25.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.